| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Mepolizumab |
| Brand | Nucala® |
| Indication | Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 16/03/2016 |
| Rapid review completed | 04/04/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 29/07/2016 |
| NCPE assessment completed | 01/03/2017 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations May 2018
